Cost drivers and financial burden for cancer-affected families in China: a systematic review
This systematic review examined cancer care costs, the financial burden for patients, and
their economic coping strategies in mainland China. We included 38 quantitative studies …
their economic coping strategies in mainland China. We included 38 quantitative studies …
Use of real world data to improve drug coverage decisions in China
W Wang, J Tan, J Wu, S Huang, Y Huang, F Xie, X Sun - bmj, 2023 - bmj.com
Use of real world data to improve drug coverage decisions in China Page 1 the bmj | BMJ
2023;381:e068911 | doi: 10.1136/bmj-2021-068911 1 HealtH tecHnology assessMent in cHina …
2023;381:e068911 | doi: 10.1136/bmj-2021-068911 1 HealtH tecHnology assessMent in cHina …
Factors influencing economic toxicity and coping strategies in lung cancer patients: a scoping review
W XiuCen, C GuiHua, L Qin, Z XiXin, T Huan - Heliyon, 2024 - cell.com
Objective A scoping review aims to identify the factors that contribute to economic
challenges for lung cancer patients, as well as effective responses to these challenges. This …
challenges for lung cancer patients, as well as effective responses to these challenges. This …
Medical insurance payment schemes and patient medical expenses: a cross-sectional study of lung cancer patients in urban China
H Hu, L Zhao, Y Yong, S Nicholas, E Maitland… - BMC Health Services …, 2023 - Springer
Background As the main cause of cancer death, lung cancer imposes seriously health and
economic burdens on individuals, families, and the health system. In China, there is no …
economic burdens on individuals, families, and the health system. In China, there is no …
Medical expenditure for lung cancer in China: a multicenter, hospital-based retrospective survey
X Zhang, JF Shi, GX Liu, JS Ren, LW Guo… - Cost Effectiveness and …, 2021 - Springer
Background Lung cancer is the most prevalent cancer, and the leading cause of cancer-
related deaths in China. The aim of this study was to estimate the direct medical expenditure …
related deaths in China. The aim of this study was to estimate the direct medical expenditure …
Costs of traditional Chinese medicine treatment for inpatients with lung cancer in China: a national study
H Nie, Z Han, S Nicholas, E Maitland, Z Huang… - … Medicine and Therapies, 2023 - Springer
Abstract Background Traditional Chinese Medicine (TCM) has long been a widely
recognized medical approach and has been covered by China's basic medical insurance …
recognized medical approach and has been covered by China's basic medical insurance …
Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective
F Li, Y Chen, D Xiao, S Jiang, Y Yang - Advances in Therapy, 2024 - Springer
Introduction The updated ORIENT-11 study demonstrated that sintilimab, when combined
with chemotherapy, had promising survival advantage compared to standard chemotherapy …
with chemotherapy, had promising survival advantage compared to standard chemotherapy …
Spending and hospital stay for melanoma in Hunan, China
X Ke, W Lin, D Li, S Zhao, M Chen, Y Xiao… - Frontiers in Public …, 2022 - frontiersin.org
Objective This study aimed to describe the economic burden of Chinese patients with
melanoma in Hunan province of China, and to investigate the factors for hospitalization …
melanoma in Hunan province of China, and to investigate the factors for hospitalization …
Optimal time‐consistent social health insurance and private health insurance strategy under a new health insurance framework
P Yang, Z Chen - Applied Stochastic Models in Business and …, 2022 - Wiley Online Library
A new continuous‐time health insurance framework is proposed to simultaneously
determine the optimal social health insurance strategy and optimal private health insurance …
determine the optimal social health insurance strategy and optimal private health insurance …
Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment …
X Liu, X Liu, W Shao, Y Zhou, J Zhang… - Frontiers in …, 2024 - frontiersin.org
Objective Both camrelizumab plus paclitaxel and carboplatin (CTC) and sintilimab plus
gemcitabine and cisplatin or carboplatin (SGP) have been approved by the National Medical …
gemcitabine and cisplatin or carboplatin (SGP) have been approved by the National Medical …